S-ClassAbout S-Class
A
ASTHAI Stock Diagnostic Report
Astrana targets $72.5M-$77.5M Q3 adjusted EBITDA while raising 2026 adjusted EBITDA to $255M-$280M
Astrana Health has raised its adjusted EBITDA forecast for 2026, presenting a positive performance outlook.
View Source Article ↗AI CATALYST SCORE85 / 100Score computed by Sentinel V12
REFERENCE PRICE$34.13Reference entry price at analysis time
01
MARKET SNAPSHOT
Key Indicators at a Glance
Major Support34.57
Near-Term Resistance49.98
02
FUNDAMENTALS
Financial & Fundamental Analysis
The upward revision of the 2026 adjusted EBITDA target raises expectations for annual revenue structure improvement, and the Q3 guidance is expected to exceed market expectations, which could contribute to improved financial soundness.
03
TECHNICAL VIEW
Technical Position & Response Criteria
The current price of $34.13 is near a support level, and the RSI of 12.8 indicates an extreme oversold condition, suggesting a potential short-term technical rebound, although the reliability is low.
Support34.57
Resistance49.98
04
CATALYST & STRATEGY
Catalyst Analysis & Forward Strategy
The upward revision of its financial targets (Q3 adjusted EBITDA $72.5M-$77.5M, 2026 $255M-$280M) is interpreted as a signal of sustainable growth based on the company's internal plans.
05
PROOF OF WORK
Analysis Point vs. Subsequent Price Action
INITIAL · At Analysis (2026-08-07)
FINAL · Current/Verified
Renders the actual stored OHLC data directly in your browser.